Cardioplegia: Definition and Administration
Cardioplegia is a specialized solution infused into the coronary circulation to induce and maintain electromechanical cardiac arrest during cardiac surgery, providing myocardial protection through hypothermia, asystole, and metabolic preservation while creating a bloodless, motionless operative field. 1
Core Mechanism and Purpose
Cardioplegia serves dual functions: it facilitates surgical precision by creating a quiet, bloodless field, and it protects the myocardium from ischemic injury during aortic cross-clamping 2. The solution acts as a selective perfusion agent that can alter or inhibit ischemic injury and prevent reperfusion damage when the aortic cross-clamp is released 2.
Types of Cardioplegia Solutions
Blood vs. Crystalloid Cardioplegia
Blood cardioplegia should be considered in selected patients—specifically those with anemia, low body surface area, chronic kidney disease, or undergoing complex procedures—to reduce hemodilution, bleeding complications, and transfusion requirements. 3, 1
Blood cardioplegia: Typically delivered 4:1 ratio of oxygenated patient blood to crystalloid component 4. Reduces hemodilution and associated complications including acute kidney injury, bleeding, and transfusion needs 1
Crystalloid cardioplegia: Pure crystalloid solutions (e.g., del Nido solution) that minimize interruptions but show no mortality benefit over conventional approaches in meta-analysis of 1,501 patients 1
Temperature Considerations
Cold cardioplegia: Most commonly used, administered intermittently every 20-30 minutes to maintain cardiac arrest and hypothermia 1
Warm/tepid cardioplegia: Developed for acute MI patients to enhance contractile function recovery. Meta-analysis of 5,879 patients showed better postoperative cardiac index and lower cardiac enzyme release, with 1.86 times lower odds of MI compared to cold cardioplegia 1. However, requires continuous, homogeneous delivery to avoid warm ischemic injury 1
Routes of Administration
Antegrade Delivery
The most commonly used mode, delivered directly into the aortic root proximal to the aortic cross-clamp at 60-100 mmHg pressure, or infused directly into coronary ostia with pressure monitoring 1. Induces cardiac arrest in 30-60 seconds 1.
Retrograde Delivery
Administered via catheter inserted into the coronary sinus at 200-400 ml/min flow, maintaining coronary sinus pressure between 30-50 mmHg (higher pressures risk venous system injury) 1. Slower arrest induction (2-4 minutes) and provides inadequate right ventricular protection 1.
Combined Approach
In complex cases with extended cross-clamp time, severe coronary disease with poorly developed collaterals, or aortic valvular insufficiency, antegrade plus retrograde cardioplegia should be used to ensure adequate distribution. 1
Administration Protocols
Standard Intermittent Dosing
Cold cardioplegia administered every 20-30 minutes to maintain arrest and hypothermia 1
Single-Shot Approach
May be applied in low-risk cases with short aortic clamp times, often using intracellular crystalloid solutions or del Nido solution. Minimizes surgical interruptions but lacks adequate evidence for high-risk operations 1
Key Guideline Recommendations
Myocardial protective strategies must be patient-centered and tailored based on clinical and pathoanatomical conditions and procedural complexity rather than relying on a fixed institutional cardioplegic solution. 3 (Class I, Level C recommendation)
Quality Control Measures
Intraoperative assessment of left and right ventricular function by transesophageal echocardiography pre- and post-cardiopulmonary bypass is recommended for immediate quality control of myocardial protection strategy in all patients, unless contraindicated. 3 Additionally, ventricular function and cardiac enzyme release should be reviewed routinely within the first 24 hours postoperatively 3.
Common Pitfalls to Avoid
- Inadequate right ventricular protection with retrograde-only cardioplegia 1
- Excessive coronary sinus pressure (>50 mmHg) causing venous injury during retrograde delivery 1
- Poor distribution or interruption of warm cardioplegia leading to anaerobic metabolism and warm ischemic injury 1
- Excessive hemodilution with crystalloid-only solutions in high-risk patients 1